All News

From the San Francisco 49ers’ Trent Williams looking back on his cancer experience to a Republican congressman returning to work after myeloma treatment, here’s what’s happening in the oncology space this week.

Patients with relapsed or refractory multiple myeloma had lower progressive disease outcomes when receiving Blenrep with Velcade and dexamethasone, research found.

Treatment for muscle-invasive bladder cancer called dose-dense MVAC did not improve survival compared with chemotherapy alone, although one drug in the combination faces a shortage.

An expert said that he is optimistic about the future use of biomarkers in the kidney cancer space.

The anxiety of cancer will seemingly never go away.

Treatment with Opdivo (nivolumab) and chemotherapy did not significantly improve progression-free survival when compared with chemotherapy alone among some patients with EGFR-mutated metastatic non-small-cell lung cancer.

The Food and Drug Administration granted a priority review to Blincyto for the treatment of early-stage CD19-positive B-cell acute lymphoblastic leukemia.

Substance use disorders, such as alcohol use disorder, were found to be more prevalent among survivors of specific cancer types, according to research.

Treatment with Tagrisso after chemoradiation resulted in patients with EGFR-mutant stage 3 non-small cell lung cancer being nearly three times less likely to experience disease progression when compared with those treated with Imfinzi or subject to observation.

The Food and Drug Administration granted a Fast Track designation to the novel drug, ARV-471 for patients with metastatic or locally advanced ER-positive, HER2-negative breast cancer.

The development of immune-related side effects is associated with improved overall survival among patients with metastatic non-small cell lung cancer (NSCLC) who receive immune checkpoint inhibitor therapy.

As a survivor, Karen Gartland found that a mind-body program was helpful, as it taught her useful techniques for when her health anxiety spikes.

“We have to make it known to people that we are not just a patient,” said Michelle Anderson-Benjamin, CEO of the Fearless Warrior Project, who received a diagnosis of metastatic breast cancer in 2022.

Certain antihypertensive medications may lower blood pressure in patients with blood cancer being treated with Imbruvica or other BTK inhibitors.

Cancer has taught me valuable lessons and now, I'm letting these lessons guide me.

The FDA has granted Priority Review to oral ALK inhibitor Alecensa (alectinib) for patients with early-stage ALK-positive non-small cell lung cancer.

Country singer Toby Keith died Monday after receiving a stomach cancer diagnosis in 2022.

Patients with advanced synovial sarcoma may have a new therapy option if the novel drug, afami-cel, is approved by the FDA after the priority review.

King Charles III received a diagnosis of cancer after a procedure for an enlarged prostate, although Buckingham Palace specified that the king does not have prostate cancer.

After a recent fiasco while trying to order prostheses and bras, I have an important question I’d like answered.

There are a few conversations patients should have with their care teams after being diagnosed with bladder cancer — especially as new treatments become more available.

One cancer vaccine may still be years away from being available, a breast cancer test may be misguiding treatments for Black women and the review of two oncology regimens are being expedited by the FDA.

I had a friend who was diagnosed with the same bladder cancer as me, though our experiences were extremely different.

For patients with advanced non-small cell lung cancer and anorexia, the use of the antidepressant Remeron has been shown to increase energy consumption, as researchers look for therapies to answer an issue faced by many patients.

Even my favorite show depicted cancer in a stereotypical way, which impacted my view on cancer when I first received my diagnosis of follicular lymphoma.

Results from the phase 3 INSPIRE study showed that treatment with Iruplinalkib reduced the risk of disease progression or death by 66% among patients with ALK-positive non-small cell lung cancer.

Slower infusion rates of antiemetic drugs may help manage nausea and vomiting in patients with gastric or gastroesophageal junction cancers.

In honor of World Cancer Day, we highlighted ongoing and successful advocacy efforts in the oncology space.